Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Bladder Urothelial Carcinoma: early-phase trial registry
4 of 14 indexed Metastatic Bladder Urothelial Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · 4 currently recruiting · #1,230 of 28,707 conditions by registered trial count
Metastatic Bladder Urothelial Carcinoma: 14 US clinical trials tracked, 4 recruiting.
Metastatic Bladder Urothelial Carcinoma is the subject of 14 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 4 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 6 of these trials.
Enrollment posture brief
Registry condition metastatic-bladder-urothelial-carcinoma
OPEN 4 | RECR 29% | LATE 4 | EARLY 9 | RANK #1230 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Acne Scars (29% recruiting · 7 trials)
Metastatic Bladder Urothelial Carcinoma lists 4 open slots (29% of 14 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Bladder Urothelial Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Bladder Urothelial Carcinoma is recruiting below its size-band peers.
4 of 14 indexed trials (28.6%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metastatic Bladder Urothelial Carcinoma research.
National Cancer Institute (NCI) accounts for 6 of 14 trials (42.9%). 7 distinct sponsors appear on at least one study for this condition label.
-
Most Metastatic Bladder Urothelial Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 70 among the 14 trials that report a genuine target (sentinel values excluded). 11 of those (78.6%) plan for fewer than 100 participants.
-
Metastatic Bladder Urothelial Carcinoma research is mostly interventional.
13 interventional and 1 observational studies make up this index (92.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
14 total, page 1 of 1
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Mayo Clinic
NCT06349642
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Mayo Clinic
NCT06764095
Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
Mayo Clinic
NCT07087860
Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors
Northwestern University
NCT06630416
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
National Cancer Institute (NCI)
NCT05092958
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer
National Cancer Institute (NCI)
NCT04579224
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
National Cancer Institute (NCI)
NCT03237780
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
National Cancer Institute (NCI)
NCT04963153
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Jonsson Comprehensive Cancer Center
NCT03582475
ARID1A and/or KDM6A Mutation and CXCL13 Expression
M.D. Anderson Cancer Center
NCT04953104
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
Emory University
NCT04848519
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy
Alliance for Clinical Trials in Oncology
NCT04637594
Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer
National Cancer Institute (NCI)
NCT02567409
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
National Cancer Institute (NCI)
NCT03513952
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 7 |
| Phase 3 | 3 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Bladder Urothelial Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Bladder Urothelial Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Bladder Urothelial Carcinoma page
14 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Metastatic Bladder Urothelial Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Metastatic Bladder Urothelial Carcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Bladder Urothelial Carcinoma condition card totals 14 registered trials; most-linked intervention Biospecimen Collection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.